HC Wainwright Reaffirms “Buy” Rating for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $11.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 48.45% from the company’s current price. HC Wainwright also issued estimates for Kamada’s Q1 2025 earnings at $0.07 EPS, Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.11 EPS and FY2029 earnings at $0.80 EPS.

Kamada Trading Up 1.2 %

Shares of NASDAQ KMDA opened at $7.41 on Thursday. Kamada has a twelve month low of $4.74 and a twelve month high of $9.15. The company has a market capitalization of $425.93 million, a price-to-earnings ratio of 26.46, a price-to-earnings-growth ratio of 0.97 and a beta of 0.99. The business has a 50 day simple moving average of $7.10 and a 200-day simple moving average of $6.15.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KMDA. Plato Investment Management Ltd bought a new position in Kamada during the 3rd quarter worth $117,000. Public Employees Retirement System of Ohio bought a new position in Kamada during the 3rd quarter worth $77,000. JPMorgan Chase & Co. bought a new position in Kamada during the 4th quarter worth $67,000. Geode Capital Management LLC grew its stake in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,549 shares during the last quarter. Finally, Aristides Capital LLC grew its stake in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.